Vis enkel innførsel

dc.contributor.authorAamodt, Anne Hege
dc.contributor.authorHøgestøl, Einar August
dc.contributor.authorPopperud, Trine Haug
dc.contributor.authorHolter, Jan Cato
dc.contributor.authorDyrhol-Riise, Anne Ma
dc.contributor.authorTonby, Kristian
dc.contributor.authorStiksrud, Birgitte
dc.contributor.authorBerge, Tone
dc.contributor.authorBarratt-Due, Andreas
dc.contributor.authorAukrust, Pål
dc.contributor.authorHeggelund, Lars
dc.contributor.authorBlennow, Kaj
dc.contributor.authorZetterberg, Henrik
dc.contributor.authorHarbo, Hanne Flinstad
dc.contributor.authorQuist‑Paulsen, Else
dc.description.abstractObjective To test the hypotheses that blood biomarkers for nervous system injury, serum concentrations of neurofilament light chain protein (NfL) and glial fibrillary acidic protein (GFAp) can serve as biomarkers for disease severity in COVID-19 patients. Methods Forty-seven inpatients with confirmed COVID-19 had blood samples drawn on admission for assessing serum biomarkers of CNS injury by Single molecule array (Simoa), NfL and GFAp. Concentrations of NfL and GFAp were analyzed in relation to symptoms, clinical signs, inflammatory biomarkers and clinical outcomes. We used multivariate linear models to test for differences in biomarker concentrations in the subgroups, accounting for confounding effects. Results In total, 21% (n = 10) of the patients were admitted to an intensive care unit, and the overall mortality rate was 13% (n = 6). Non-survivors had higher serum concentrations of NfL (p < 0.001) upon admission than patients who were discharged alive both in adjusted analyses (p = 2.6 × 10–7) and unadjusted analyses (p = 0.001). The concentrations of NfL in non-survivors increased over repeated measurements; whereas, the concentrations in survivors were stable. The GFAp concentration was also significantly higher in non-survivors than survivors (p = 0.02). Conclusion Increased concentrations of NfL and GFAp in COVID-19 patients on admission may indicate increased mortality risk. Measurement of blood biomarkers for nervous system injury can be useful to detect and monitor CNS injury in COVID-19.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleBlood neurofilament light concentration at admittance: a potential prognostic marker in COVID‑19en_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright The Author(s) 2021en_US
dc.source.journalJournal of Neurologyen_US
dc.identifier.citationJournal of Neurology, 2021.en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal